Medicure Inc. (MPH) Earnings Call Transcripts
Medicure Inc.'s Latest Earnings Call - Q1 FY2026
In the first quarter of fiscal 2026, Medicure Inc. reported a significant increase in net revenue to $7.9 million, up from $5.5 million in Q1 2025, driven by growth in ZYPITAMAG and Marley Drug sales. The company incurred a net loss of $406,000, an improvement from a loss of $694,000 in the prior year, attributed to ongoing investments in R&D, particularly for the MC-1 therapy. Management maintained a positive outlook on revenue growth, particularly through its pharmacy acquisitions and ongoing clinical trials, signaling potential future value creation for shareholders.
Reported metrics
| Metric | Value |
|---|---|
| Net Revenue | $7.9 million (beat) |
| Net Loss | $406,000 (beat) |
| ZYPITAMAG Revenue | $1.3 million (beat) |
| Marley Drug Revenue | $3.2 million (beat) |
| R&D Expenses | $855,000 (miss) |
| Cost of Goods Sold | $4.4 million (miss) |
Guidance from management
Management remains focused on growing revenue through acquisitions and R&D investments, particularly in the MC-1 therapy, with a target to complete patient enrollment by June 2026.
What management said
Thank you. Thank you for all of you that are on the call. I appreciate your interest and we welcome you to continue to follow. And if you have any questions, contact us directly, and look forward to the Q2 call. Thanks again.
What analysts pressed on
Analysts expressed concerns regarding the rising cost of goods sold and its impact on profitability. There were also questions about the sustainability of revenue growth from ZYPITAMAG amidst increasing competition.
Main topics on the call
- Revenue Growth — Medicure's net revenue increased to $7.9 million in Q1 2026 from $5.5 million in Q1 2025, indicating a strong growth trajectory. CEO Dr. Friesen noted, "Overall, the company's revenue increased," highlighting the impact ...
- ZYPITAMAG Performance — Revenue from ZYPITAMAG rose to $1.3 million from $519,000 year-over-year, attributed to higher utilization through insurance formularies. Management emphasized the focus on growing ZYPITAMAG revenue through both insured ...
- Marley Drug Growth — Marley Drug generated $3.2 million in revenue, slightly up from $3.1 million in Q1 2025. The increase was driven by higher sales of ZYPITAMAG and BRENZAVVY, showcasing the effectiveness of the direct distribution strateg...
- R&D Investment — R&D expenses increased to $855,000 from $570,000, primarily for the MC-1 therapy development. Dr. Friesen stated that the company is committed to advancing innovative therapies, which is crucial for long-term growth.
Read the full Medicure Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Medicure Inc.
Medicure Inc. (MPH) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on TSXV and is based in CA. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 25 calls on record spanning April 16, 2020 to August 17, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 25 Medicure Inc. earnings call transcripts on record, spanning April 16, 2020 to August 17, 2026. Based on this history, Medicure Inc. reports quarterly. The most recent call on file is dated August 17, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- MPH
- Exchange
- TSXV
- Country
- CA
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 25
- First call
- April 16, 2020
- Most recent
- August 17, 2026
- Reporting cadence
- quarterly